YIPF6

Across TCGA pan-cancer cohorts, YIPF6 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of YIPF6’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where YIPF6 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types YIPF6 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where YIPF6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in YIPF6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.420	<.001	12	view →
COAD	Male	II,III,IV	+0.275	<.001	8	view →
LSCC	All	All	+0.234	<.001	8	view →
PDAC	All	III,IV	+0.624	<.001	7	view →
LUAD	Female	II,III,IV	+0.410	<.001	6	view →
CCRCC	Male	All	−0.103	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

YIPF6–HNSC

Open the HNSC breakdown →